FIELD: biotechnology; medicine.
SUBSTANCE: invention relates to biotechnology and medicine, in particular to a method for assessing the potential of anticancer therapeutic agents to cause skin side effects. Method comprises using a three-dimensional model of the epidermis, demonstrating differentiating keratinocytes in the reconstructed stratum corneum, wherein the model contains an anticancer therapeutic agent in an amount effective for simulating the chronic effect of the drug. Also disclosed is use of said model for testing the composition to determine whether the composition can prevent the effect of said anticancer therapeutic agent on the structure and function of the skin barrier.
EFFECT: method enables assessing the ability of the anticancer therapeutic agents to cause skin side effects, as well as the efficacy of the compositions in reducing the effect of the anticancer therapeutic agents on the skin.
6 cl, 5 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR EVALUATING EFFICACY OF COMPOSITION FOR REDUCING EFFECT OF ANTICANCER THERAPEUTIC AGENTS ON SKIN | 2020 |
|
RU2829863C1 |
| IMPROVED DIFFERENTIATION METHOD | 2017 |
|
RU2772435C2 |
| SELECTION OF MEDICATIONS FOR LUNG CANCER THERAPY BY MEANS OF ANTIBODY-BASED MATRICES | 2008 |
|
RU2519647C2 |
| NOVEL SMALL MOLECULES FOR TARGETED SPLITTING OF NON-SUSCEPTIBLE KRAS IN CANCER THERAPY | 2021 |
|
RU2839932C1 |
| METHOD OF PRODUCTION OF T-CELLS | 2015 |
|
RU2813668C2 |
| IMPROVED COMPOSITIONS BASED ON T-CELLS | 2015 |
|
RU2719030C2 |
| HORMONE D (VITAMIN D) AND ITS DERIVATIVES FOR THE TREATMENT AND PREVENTION OF CANCER | 2019 |
|
RU2794340C1 |
| THERAPEUTIC USE OF MEDICINAL FORMS OF BERBERINE | 2016 |
|
RU2733743C2 |
| RECEPTOR ANTAGONISTS FOR TREATING METASTATIC CANCER | 2009 |
|
RU2455026C2 |
| PDGFRα ANTIBODIES FOR TREATING SECONDARY BONE TUMOUR | 2006 |
|
RU2502523C2 |
